Inactive Instrument

Insiders Obalon Therapeutics Inc Nasdaq

Equities

US67424L1008

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

Reshape Lifesciences Announces Formation of International Scientific Advisory Board	23-03-23	CI
Reshape Lifesciences Inc. Appoints Nick Ansari, as Senior Vice President of Global Commercial Operations	22-08-23	CI
ReShape Lifesciences Appoints Paul F. Hickey as President and Member of the Board of Directors, Effective August 15, 2022	22-07-27	CI
ReShape Lifesciences Appoints Paul F. Hickey as Chief Executive Officer, Effective August 15, 2022	22-07-27	CI
ReShape Lifesciences Inc. Appoints Michael Bordainick as Senior Vice President, Commercial Operations	22-01-13	CI
Insider Trends: Insider 90-Day Selling Trend Extended at ReShape Lifesciences	21-06-22	MT
Obalon Therapeutics, Inc. has Changed its Name to ReShape Lifesciences Inc	21-06-15	CI
Obalon Therapeutics, Inc. Announces Resignation of David Moatazedi as Member of the Board, the Compensation Committee, and the Audit Committee	20-07-02	CI
Obalon Therapeutics, Inc. Appoints Kim Kamdar as Chairperson of the Board of Directors	20-06-30	CI
Obalon Therapeutics, Inc. Announces Management Changes	20-05-08	CI
Obalon Therapeutics, Inc. Appoints William J. Plovanic as Chief Executive Officer and Nooshin Hussainy as Chief Financial Officer	19-10-24	CI
Obalon Therapeutics, Inc. Appoints Helmuth T. Billy as Medical Director	19-09-03	CI
ReShape Lifesciences Inc. Announces Resignation of Scott P. Youngstrom as Senior Vice President, Finance and Chief Financial Officer, Effective October 1, 2019	19-08-06	CI
Obalon Therapeutics, Inc. Appoints Bob MacDonald as Chief Retail Officer	19-06-10	CI
Obalon Therapeutics, Inc. Announces Management Changes	19-05-22	CI
ReShape Lifesciences Inc. Appoints Barton P. Bandy as President and Chief Executive Officer	19-04-01	CI
Dan W. Gladney to Resign as President and Chief Executive Officer of Reshape Lifesciences Inc., Effective as of March 31, 2019	19-01-28	CI
Obalon Therapeutics, Inc. Announces Promotion of Amy Vandenberg to Chief Clinical & Regulatory Affairs Officer	19-01-03	CI
Obalon Therapeutics, Inc. Announces Executive Changes	19-01-02	CI
Obalon Therapeutics, Inc. Announces Executive Appointments	18-11-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders Obalon Therapeutics Inc Nasdaq

Equities

US67424L1008

Insiders

Filters